• 54
  • 8
  • 收藏

China's Kintor says interim analysis of COVID treatment trial misses statistical criteria

Reuters2021-12-28

BEIJING, Dec 27 (Reuters) - China's Kintor Pharmaceutical Ltd(9939.HK)said data from a Phase III clinical trial for its potential COVID-19 treatment proxalutamide in non-hospitalised patients did not meet statistical criteria in the interim analysis due to the low number of hospitalisations.

"In a trial that had enrolled 348 people for interim analysis, a limited number of participants whose illness progressed from mild or moderate symptoms to the degree that required hospitalization was reported," a Kintor representative said on Monday.

The low number resulted in the lack of statistical significance in data analysis between placebo group and the group where participants took the proxalutamide tablet, the representative said, without disclosing detailed readings.

Kintor said in a filing on Monday that it will seek consent from authorities, including U.S. Food and Drug Administration, to amend clinical protocol and continue to enroll patients of higher risk, such as those who have not received a COVID-19 vaccination.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论8

  • jojoc
    ·2021-12-28
    Ok
    回复
    举报
  • iamme
    ·2021-12-28
    Ok
    回复
    举报
  • ivy888
    ·2021-12-28
    Like 
    回复
    举报
  • nelson21
    ·2021-12-28
    Pls like
    回复
    举报
    收起
    • ivy888
      ok
      2021-12-28
      回复
      举报
  • SALLY123
    ·2021-12-28
    oo
    回复
    举报
  • ERIC KHOO SG
    ·2021-12-28
    Dont spread fud please
    回复
    举报
    收起
    • iamme
      ok
      2021-12-28
      回复
      举报
  • Spng
    ·2021-12-28
    Hi
    回复
    举报
    收起
    • Spng
      hello
      2021-12-28
      回复
      举报
  • Spng
    ·2021-12-28
    Hi
    回复
    举报
 
 
 
 

热议股票

 
 
 
 
 

7x24